About transmedics group inc - TMDX
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
TMDX At a Glance
TransMedics Group, Inc.
200 Minuteman Road
Andover, Massachusetts 01810
| Phone | 1-978-552-0900 | Revenue | 605.49M | |
| Industry | Medical Specialties | Net Income | 190.29M | |
| Sector | Health Technology | 2025 Sales Growth | 37.132% | |
| Fiscal Year-end | 12 / 2026 | Employees | 898 | |
| View SEC Filings |
TMDX Valuation
| P/E Current | 16.381 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 24.962 |
| Price to Sales Ratio | 8.145 |
| Price to Book Ratio | 8.811 |
| Price to Cash Flow Ratio | 25.57 |
| Enterprise Value to EBITDA | 36.553 |
| Enterprise Value to Sales | 8.196 |
| Total Debt to Enterprise Value | 0.105 |
TMDX Efficiency
| Revenue/Employee | 674,269.488 |
| Income Per Employee | 211,905.345 |
| Receivables Turnover | 7.184 |
| Total Asset Turnover | 0.622 |
TMDX Liquidity
| Current Ratio | 7.142 |
| Quick Ratio | 6.594 |
| Cash Ratio | 5.469 |
TMDX Profitability
| Gross Margin | 59.886 |
| Operating Margin | 17.933 |
| Pretax Margin | 17.758 |
| Net Margin | 31.427 |
| Return on Assets | 19.546 |
| Return on Equity | 54.237 |
| Return on Total Capital | 19.175 |
| Return on Invested Capital | 22.085 |
TMDX Capital Structure
| Total Debt to Total Equity | 109.761 |
| Total Debt to Total Capital | 52.327 |
| Total Debt to Total Assets | 46.418 |
| Long-Term Debt to Equity | 106.947 |
| Long-Term Debt to Total Capital | 50.985 |